StrongDecrease
Body weight
Semaglutide → Body weight
Semaglutide → Body weight
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Oral semaglutide improves glycemic control in type 2 diabetes
Key finding
The estimated treatment difference (ETD [95% CI]) was -2 (-4, -1) mmol/mol.
This study compared the efficacy and safety of oral semaglutide to sitagliptin in adults with inadequately controlled type 2 diabetes. Results indicated that oral semaglutide led to significantly greater reductions in HbA1c and body weight.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Some Concerns bias
Last updated July 5, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Oral Semaglutide 3 mg, Oral Semaglutide 7 mg, Oral Semaglutide 14 mg, Oral Sitagliptin 100 mg
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Primary outcome
HbA1c
Comparator
Oral Sitagliptin 100 mg
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study compared the efficacy and safety of oral semaglutide to sitagliptin in adults with inadequately controlled type 2 diabetes. Results indicated that oral semaglutide led to significantly greater reductions in HbA1c and body weight.
Clinical relevance
These findings are significant for clinicians treating patients with type 2 diabetes, as they highlight the potential of oral semaglutide as a more effective alternative to sitagliptin. Improved glycemic control and weight loss can lead to better overall health outcomes for patients, reducing the risk of diabetes-related complications.
Keep in mind
The study's population may not be representative of all adults with type 2 diabetes. Limited long-term safety data beyond 26 weeks. Potential for bias due to the open-label design.
Published in
Journal Reference
Publication details and source links for this paper.
Linong J, Rikke MA, Stephen CB, et al. Efficacy and safety of oral semaglutide vs sitagliptin in adults with type 2 diabetes inadequately controlled with metformin. Diabetologia. 2024;67(9):1800-1816. doi:10.1007/s00125-024-06133-4
Save this study and add notes to your research library.
Main Effects
Oral semaglutide reduced HbA1c by -2 mmol/mol (p=0.001).
Body weight decreased by -0.9 kg with oral semaglutide (p=0.001).
Oral semaglutide led to a reduction in HbA1c by -8 mmol/mol (p=0.001).
Body weight decreased by -2.3 kg with oral semaglutide (p=0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Semaglutide, Sitagliptin and Body weight, HbA1c.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
- Body weight
- HbA1c
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
4
Related topics
4
Evidence pairs
302
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
StrongDecrease
HbA1c
Semaglutide → HbA1c
Semaglutide → HbA1c
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
StrongDecrease
Body weight
Sitagliptin → Body weight
Sitagliptin → Body weight
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
StrongDecrease
HbA1c
Sitagliptin → HbA1c
Sitagliptin → HbA1c
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Oral semaglutide showed a significant reduction in HbA1c levels.
- Participants experienced greater weight loss with oral semaglutide compared to sitagliptin.
- Statistical significance was achieved for both HbA1c and body weight outcomes.
Who this applies to
- Adults with type 2 diabetes inadequately controlled with metformin.
- Patients seeking alternative oral medications for diabetes management.
Keep in Mind
- Results may not generalize to populations outside the study.
- Further research is needed to assess long-term effects.
- The study's design may introduce biases that could affect outcomes.
Between the Lines
- The study's population may not be representative of all adults with type 2 diabetes.
- Limited long-term safety data beyond 26 weeks.
- Potential for bias due to the open-label design.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
11 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
11 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
10 studies
outcome_hubMeasures Body Weight as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Semaglutide and HbA1c
Intervention: SemaglutideOutcome: HbA1c
11 results
All studies on Semaglutide and Body weight
Intervention: SemaglutideOutcome: Body weight
10 results
All studies on Semaglutide
Intervention: Semaglutide
11 results
All studies measuring HbA1c
Outcome: HbA1c
11 results
All studies measuring Body weight
Outcome: Body weight
10 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve HbA1c?
Moderate Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.8 | strong positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 24 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body weight?
Emerging Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 66.2 | moderate positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 23 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does DPP-4 Inhibitors improve HbA1c?
Emerging Evidence
DPP-4 Inhibitors appears to improve HbA1c.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 57.7 | strong positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does DPP-4 Inhibitors affect body weight?
Emerging Evidence
DPP-4 Inhibitors may improve Body Weight.
ConsensusScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 45.9 | moderate positive | ConsensusScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesOral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic Control
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.